ciltacabtagene autoleucel
janssen,Nanjing Legend Biotech
['cartitude-1', 'cartitude', 'cilta-cel', 'mmsm']
#eha2023 | nikhil munshi presents the final results from the cartitude-1 trial of cilta-cel in rrmm. median pfs 34.9 months, orr 97.9%. median os not reached, at 36-mo estimated os 62.9%. #mmsm #myeloma 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma